New injection Y-3 put to the test: will it clash with common drugs?
NCT ID NCT07068841
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed Phase 1 trial in 24 healthy adults checked whether an experimental injection called Y-3 changes how the body handles three common drugs: repaglinide (for diabetes), warfarin (a blood thinner), and omeprazole (for heartburn). Participants took these drugs alone and then again while receiving Y-3. The goal was to see if Y-3 causes drug interactions, which would affect dosing instructions. This is a safety and drug-level study, not a treatment trial.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Y-3 for injection
What this could lead to
If successful, this study could help doctors understand whether Y-3 injection can be safely used with common medications like repaglinide, warfarin, and omeprazole.
What could go wrong
This is a very early, small study in healthy volunteers, not patients. It only looks at drug levels in the blood, not actual treatment outcomes. Results may not apply to people with medical conditions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DRUG-DRUG INTERACTION are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The First Affiliated Hospital of Bengbu Medical College
Bengbu, Anhui, China